220 related articles for article (PubMed ID: 30880918)
1. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.
Zhou T; Lin S; Yang S; Lin W
Drug Des Devel Ther; 2019; 13():857-869. PubMed ID: 30880918
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy and Safety of Tacrolimus, Cyclosporin A, Mycophenolate Mofetil, Cyclophosphamide, and Corticosteroids as Induction Therapy for Membranous Lupus Nephritis: A Network Meta-Analysis.
Lee YH; Song GG
Pharmacology; 2022; 107(9-10):439-445. PubMed ID: 35609529
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Jiang N; Jin S; Yu C; Zhao J; Wang Q; Tian X; Li M; Zeng X
Front Immunol; 2023; 14():1232244. PubMed ID: 37901212
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
[TBL] [Abstract][Full Text] [Related]
7. Multitarget Therapy: An Effective and Safe Therapeutic Regimen for Lupus Nephritis.
Zhou T; Zhang X; Lin W; Lin S
J Pharm Pharm Sci; 2019; 22(1):365-375. PubMed ID: 31580800
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.
Hannah J; Casian A; D'Cruz D
Autoimmun Rev; 2016 Jan; 15(1):93-101. PubMed ID: 26427983
[TBL] [Abstract][Full Text] [Related]
9. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis.
Li HY; Zhang X; Zhou T; Zhong Z; Zhong H
BMC Nephrol; 2019 Oct; 20(1):384. PubMed ID: 31646979
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
[TBL] [Abstract][Full Text] [Related]
14. Multitarget therapy versus monotherapy as induction treatment for lupus nephritis: A meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2022 Oct; 31(12):1468-1476. PubMed ID: 35986446
[TBL] [Abstract][Full Text] [Related]
15. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.
Zhang X; Ji L; Yang L; Tang X; Qin W
Int Urol Nephrol; 2016 May; 48(5):731-43. PubMed ID: 26781720
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus versus mycophenolate mofetil as induction treatment and low-dose tacrolimus as treatment for lupus nephritis: a meta-analysis.
Lee YH; Song GG
Z Rheumatol; 2023 Nov; 82(9):754-762. PubMed ID: 36607421
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.
Tian SY; Feldman BM; Beyene J; Brown PE; Uleryk EM; Silverman ED
J Rheumatol; 2014 Oct; 41(10):1998-2007. PubMed ID: 25225281
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.
Li K; Yu Y; Gao Y; Zhao F; Liang Z; Gao J
Front Immunol; 2022; 13():859380. PubMed ID: 35444666
[TBL] [Abstract][Full Text] [Related]
19. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis.
Singh JA; Hossain A; Kotb A; Wells G
BMC Med; 2016 Sep; 14(1):137. PubMed ID: 27623861
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
